Overview

LEO 32731 - A Phase I Study in Healthy Subjects

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor") for treatment of psoriasis. The aim (s) of this Study are to determine: - The safety and tolerability of the Study Drug and any side effects that might be associated with it - The Study will also measure how much of the Study Drug that gets into the blood and how long time it takes for the body to remove it.
Phase:
Phase 1
Details
Lead Sponsor:
LEO Pharma